記述言語：日本語   出版者・発行元：(一社)日本消化器内視鏡学会-関東支部  

昨今,多様な働き方が求められる中で,個々の内視鏡医の置かれている環境も多様となった.個々人での知識のアップデートが難しいケースもある.そのため,学習やネットワーキングのための多様な選択肢を用意し,各々にとって,学びやすい環境を作る事が求められる.本稿では,生涯学習およびネットワーキングの方法の一つ(あくまで一つ)として,ソーシャルメディアを用いた学びの提案を行うとともに,実際の運用を例として,その利点,問題点に関しても触れる.(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J04450&link_issn=&doc_id=20240116120002&doc_link_id=%2Fdw9poden%2F2023%2F010301%2F014%2F0029-0035%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdw9poden%2F2023%2F010301%2F014%2F0029-0035%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND AND AIM: In this retrospective study, we evaluated the effects of pemafibrate treatment in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia using non-invasive stiffness-based models, including magnetic resonance elastography (MRE) combined with the fibrosis-4 (FIB-4) (MEFIB) index and the magnetic resonance imaging (MRI)-aspartate aminotransferase (AST) (MAST) score. METHODS: In total, 179 patients with MASLD treated with pemafibrate were enrolled. We evaluated the effects of 48-week pemafibrate treatment using the MEFIB index, which classifies patients based on the combination of liver stiffness measurement (LSM) on MRE and FIB-4 and the MAST score, which is calculated based on LSM on MRE, MRI-proton density fat fraction (MRI-PDFF), and AST levels. RESULTS: Pemafibrate treatment led to significant reduction in AST, alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT) (P = 0.011, <0.001, and <0.001, respectively) and significant improvements in triglyceride and high-density lipoprotein cholesterol levels (P < 0.001 and <0.001, respectively). The MRI-PDFF values were not significantly altered. However, a significant decrease in LSM on MRE was detected (P = 0.003). Evaluation of fibrosis using the MEFIB index and MAST score demonstrated significant improvement (P = 0.004 and <0.001, respectively). Changes in the MAST score showed positive correlation with changes in ALT and GGT levels (r = 0.821, P < 0.001, and r = 0.808, P < 0.001, respectively). Additionally, ALT and GGT levels at baseline were significantly associated with improvements in the MAST score (P < 0.001 and <0.001, respectively). CONCLUSION: Pemafibrate led to improvements in the MEFIB index and MAST score, as well as liver function. It is a promising therapeutic agent for patients with MASLD and hypertriglyceridemia with the potential to reduce liver-related events.

DOI： 10.1002/jgh3.13012

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: The spread of coronavirus disease 2019 (COVID-19) had a major impact on the health of people worldwide. The clinical background and clinical course of inflammatory bowel disease (IBD) among Japanese patients with COVID-19 remains unclear. METHODS: This study is an observational cohort of Japanese IBD patients diagnosed with COVID-19. Data on age, sex, IBD (classification, treatment, and activity), COVID-19 symptoms and severity, and treatment of COVID-19 were analyzed. RESULTS: From 72 participating facilities in Japan, 187 patients were registered from June 2020 to October 2021. The estimated incidence of COVID19 in Japanese IBD patients was 0.61%. The majority of IBD patients with COVID-19 (73%) were in clinical remission. According to the WHO classification regarding COVID-19 severity, 93% (172/184) of IBD patients had non-severe episodes, while 7% (12/184) were severe cases including serious conditions. 90.9% (165/187) of IBD patients with COVID-19 had no change in IBD disease activity. A logistic regression analysis stepwise method revealed that older age, higher body mass index (BMI), and steroid use were independent risk factors for COVID-19 severity. Six of nine patients who had COVID-19 after vaccination were receiving anti-tumor necrosis factor (TNF)-α antibodies. CONCLUSION: Age, BMI and steroid use were associated with COVID-19 severity in Japanese IBD patients.

DOI： 10.1007/s00535-022-01851-1

PubMed

researchmap

researchmap

記述言語：日本語   出版者・発行元：神奈川県医師会  

researchmap

記述言語：日本語   出版者・発行元：(株)南江堂  

＜文献概要＞・全炎症性腸疾患(IBD)患者の約25%は18歳未満で診断され,思春期においても,決してまれな疾患ではない.・まずは疑うことから始まる.長期的(1ヵ月以上)に続く下痢,血便,腹痛に関しては潰瘍性大腸炎(UC)を,さらに発熱や肛門病変(痔瘻など)が伴った場合はCrohn病(CD)を念頭に置いて精査を行う.・患者は,治療の過程で,進学,就職,結婚,出産といったライフイベントを経験することになる.そのため,早期の診断と的確なモニタリングと治療により,よいタイミングで寛解を維持していることが重要である.

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J00974&link_issn=&doc_id=20230302080009&doc_link_id=10.15106%2Fj_naika131_366&url=https%3A%2F%2Fdoi.org%2F10.15106%2Fj_naika131_366&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

開催年月日： 2022年10月

記述言語：日本語  

researchmap

開催年月日： 2021年11月

記述言語：日本語  

researchmap

開催年月日： 2021年10月

記述言語：日本語  

researchmap

開催年月日： 2021年9月

記述言語：日本語  

researchmap

researchmap

researchmap

researchmap

researchmap